Home › Multiple Myeloma › Alabama
Multiple Myeloma clinical trials in Alabama
22 studies for Multiple Myeloma are looking for participants at sites in Alabama.
Cities in Alabama
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Infirmary Cancer Care, Mobile
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06152575A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- University of Alabama Birmingham, Birmingham
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT04634552A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
- Clearview Cancer Institute, Huntsville
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 30, 2026 · NCT07284758A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
- University of Alabama at Birmingham, Birmingham
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 29, 2026 · NCT06615479A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
- Gulf Health Hospitals, Inc. d/b/a Infirmary Cancer Care - Malbis, Daphne
- Gulf Health Hospitals, Inc. d/b/a Thomas Medical Center, Daphne
- Gulf Health Hospitals, Inc. d/b/a Infirmary Cancer Care - Fairhope, Fairhope
- and 4 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 27, 2026 · NCT05623020A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- University of Alabama At Birmingham Hospital, Birmingham
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT04973605A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
- Infirmary Health - Diagnostic & Medical Clinic (DMC), Mobile
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 13, 2026 · NCT06980480AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
- Research Site, Birmingham
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 8, 2026 · NCT05850234Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- University of Alabama at Birmingham, Birmingham
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 6, 2026 · NCT06297226A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Alabama Oncology, Birmingham
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07518186A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
- University of Alabama at Birmingham Hospital, Birmingham
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT07116616TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham
RecruitingPhase 2
Ages 12 and older · All sexes · Updated Sep 22, 2026 · NCT02693535A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
- University of Alabama at Birmingham, Birmingham
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT06988488A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
- University of Alabama at Birmingham, Birmingham
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 16, 2026 · NCT06121843Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
- University of Alabama at Birmingham, Birmingham
RecruitingPhase 2
Ages 19 and older · All sexes · Updated Jun 4, 2026 · NCT06974786A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
- GSK Investigational Site, Mobile
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Apr 22, 2026 · NCT06679101A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
- University of Alabama at Birmingham, Birmingham
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Mar 18, 2026 · NCT06153251Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)
- University of Alabama at Birmingham, Birmingham
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Dec 31, 2025 · NCT04991103Prehabilitation Feasibility Among Older Adults Undergoing Transplantation
- Kirklin Clinic of UAB Hospital, Birmingham
Recruiting
Ages 60 and older · All sexes · Updated Dec 24, 2025 · NCT05642884Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry
- Kirklin Clinic of UAB Hospital, Birmingham
RecruitingObservational study
Ages 50 and older · All sexes · Updated Dec 8, 2025 · NCT05556928CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
- University of Alabama at Birmingham, Birmingham
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 25, 2025 · NCT05722418A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
- UAB Comprehensive Cancer Center, Birmingham
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 5, 2025 · NCT05372354From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.